Targeting vaccines to dendritic cells

Pharmaceutical Research

Volumn 19, Issue 3, 2002, Pages 229-238

  Foged, C ^a,b   Sundblad, A ^b   Hovgaard, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dendritic cells; Drug delivery; Formulation; Review; Targeting; Vaccine

Indexed keywords

VACCINE;

ANTIGEN PRESENTING CELL; CELLULAR DISTRIBUTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANIMALS; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; VACCINATION; VACCINES;

EID: 0036197499     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014474414097     Document Type: Review

References (61)

1. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
2. Advances in vaccine adjuvants
3. Immunobiology of dendritic cells
4. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin
5. Dendritic cells: Unique leukocyte populations which control the primary immune response
6. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
7. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
8. The endocytic activity of dendritic cells
9. The role of aquaporins in dendritic cell macropinocytosis
10. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing
11. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells
12. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo
13. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation
14. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
15. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
16. DNA vaccination: Transfection and activation of den-dritic cells as key events for immunity
17. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
18. Effect of interleukin-10 on dendritic cell maturation and function
19. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells
20. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate
21. Oligosaccharides of hyaluronan are potent activators of dendritic cells
22. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
23. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells
24. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
25. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
26. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
27. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells
28. Antigen capture, processing, and presentation by dendritic cells: Recent cell biologic studies
29. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells
30. Efficient major histocompatibility complex class I presentation of exogenous antigen on phagocytosis by macrophages
31. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells
32. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation
33. Origin, maturation and antigen presenting function of dendritic cells
34. Dendritic cell based tumor vaccines
35. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?
36. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells
37. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis
38. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand
39. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
40. Targeting dendritic cells to enhance DNA vaccine potency
41. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine
42. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I
43. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
44. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells
45. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells
46. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells
47. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments
48. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
49. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep
50. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep
51. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
52. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
53. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model
54. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
55. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis
56. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant
57. Modulating the immune response with dendritic cells and their growth factors
58. Fully mobilizing host defense: Building better vaccines
59. Antigens linked to synthetic microspheres induce immune responses in primates in the absence of adjuvant
60. Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery
61. Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells?